CD1D and neoplasm: Epigenetic modifications such as methylation of the TME can impact genes like beta-2-microglobulin (β2M) and Spi-1-proto-oncogene (SPI1), which control CD1D expression that is crucial for tumor antigen presentation and immune recognition [46].